Statin modulates insulin signaling and insulin resistance in liver and muscle of rats fed a high-fat diet.
Recent studies have shown that statins might have relevant effects on insulin resistance in animal models and in humans. However, the molecular mechanisms that account for this improvement in insulin sensitivity are not well established. The aim of the present study was to investigate the effect of a statin on insulin sensitivity and insulin signaling in liver and muscle of rats fed on a high-fat diet (HFD) for 4 weeks, treated or not with lovastatin during the last week. Our data show that treatment with lovastatin results in a marked improvement in insulin sensitivity characterized by an increase in glucose disappearance rate during the insulin tolerance test. This increase in insulin sensitivity was associated with an increase in insulin-induced insulin receptor (IR) tyrosine phosphorylation and, in parallel, a decrease in IR serine phosphorylation and association with PTP1B. Our data also show that lovastatin treatment was associated with an increase in insulin-stimulated insulin receptor substrate (IRS) 1/phosphatidylinositol 3-kinase/Akt pathway in the liver and muscle of HFD-fed rats in parallel with a decrease in the inflammatory pathway (c-jun N-terminal kinase and I kappa beta kinase (IKKbeta)/inhibitor of kappaB/nuclear factor kappaB) related to insulin resistance. In summary, statin treatment improves insulin sensitivity in HFD-fed rats by reversing the decrease in the insulin-stimulated IRS-1/phosphatidylinositol 3-kinase/Akt pathway in liver and muscle. The effect of statins on insulin action is further supported by our findings that HFD rats treated with statin show a reduction in IRS-1 serine phosphorylation, I kappa kinase (IKK)/inhibitor of kappaB/nuclear factor kappaB pathway, and c-jun N-terminal kinase activity, associated with an improvement in insulin action. Overall, these results provide important new insight into the mechanism of statin action in insulin sensitivity.
Lalli
Cristina Alba
CA
Departamento de Clínica Médica, FCM, Universidade Estadual de Campinas (UNICAMP) 13081-970 Campinas, SP, Brazil.
Pauli
José Rodrigo
JR
Prada
Patrícia Oliveira
PO
Cintra
Dennys Esper
DE
Ropelle
Eduardo Rochette
ER
Velloso
Lício Augusto
LA
Saad
Mario José Abdalla
MJ
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight; D004041:Dietary Fats / Q000494:pharmacology*; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D007328:Insulin / Q000097:blood / Q000494:pharmacology / Q000502:physiology*; D007333:Insulin Resistance / Q000502:physiology*; D008099:Liver / Q000187:drug effects / Q000502:physiology*; D008148:Lovastatin / Q000494:pharmacology*; D008297:Male; D018482:Muscle, Skeletal / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar; D015398:Signal Transduction / Q000187:drug effects
D001786:Blood Glucose; D004041:Dietary Fats; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007328:Insulin; D008148:Lovastatin